Mirum Pharmaceuticals (MIRM)

Mirum’s best-known product is Livmarli, the brand name for maralixibat, an oral ileal bile acid transporter, or IBAT, inhibitor. By reducing the recycling of bile acids in the intestine, the therapy is designed to help manage cholestatic pruritus associated with rare paediatric liver diseases such as Alagille syndrome and progressive familial intrahepatic cholestasis. Severe itching can be one of the most burdensome symptoms in these conditions, making symptom control an important clinical goal.

The company’s commercial portfolio also includes Cholbam and Ctexli, medicines used in rare bile acid-related disorders. Together with Livmarli, these products give Mirum a revenue base beyond a single asset while reinforcing its specialist position in hepatology and inherited metabolic disease.

Mirum continues to develop maralixibat for additional uses and is advancing volixibat, another IBAT inhibitor, for adult cholestatic liver diseases. This pipeline strategy allows the company to build on established scientific knowledge around bile acid biology while targeting distinct patient groups and disease settings.

For investors, Mirum stands out as a commercial-stage rare-disease biotechnology company. Its performance is linked to uptake of approved medicines, expansion into new indications, payer access, clinical trial results, and the company’s ability to serve specialised physician and patient communities.